维普中文期刊产品整合服务
10篇 您的检索式:作者名="Mahboudi"
    题名 作者 年代 出处 被引量
1Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24,gp41,gp120 and gp36 antigens显示文摘RAVANSHAD M SABAHI F MAHBOUDI F 2006Journal of Saudi Medicine2006,27,1:1
2Regulatory aspec ts of cl onallyexpanded B1(CD5+B)cells显示文摘Raveche E S,Philips J,Mahboudi F 1992Int J Clin Lab Res,1992,22,220:1
3Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice显示文摘Mahmoud R. Jaafari Attieh Ghafarian Ahsan Farrokh-Gisour Afshin Samiei Masoumeh Tavassoti Kheiri Fereidoun Mahboudi Farzaneh Barkhordari Ali Khamesipour W. Robert McMaster 2006Vaccine2006,,29:1
4A cultured malignant B-1 line serves as a model for Richter's syndrome显示文摘Peng B Sherr DH Mahboudi F 1994J Immunol1994,153,4:1
5The role of different supplements in expression level of monoclonal antibody against human CD20显示文摘MAHBOUDI F ABOLHASSAN M R AZARPANAH A 2013Avicenna J Med Biotechnol2013,5,3:1
6Indeterminate human immunodeficiency virus western blot results in Iranian patients with discordant screening assay results显示文摘Ravanshad M Mahboudi F Sabahi F 2006Saudi Med J2006,27,8:1
7An accurate confirmation of human immunodeficiency virus type 1 (HIV-1) and 2 (HIV-2)infections with a dot blot assay using recombinant p24,gp41,gp120显示文摘Ravanshad M Sabahi F Mahboudi F 2004Int J Med Sci2004,1,:1
8An accurate confirmation of human imrnunodeficiency virus type 1 (HIV 1) and 2 (HIV-2) infections with a dot blot assay using recombinant p24, gp41, gpl20 and gp36 Antigens 显示文摘Ravanshad M Sabahl F Mahboudi F 2004IntJ MedScl2004,1,3:1
9The effect of different stabilizers on stability of horseradish peroxidase-bovine serum albumin-aflatoxin B1, a conjugated tracer for detection of aflatoxin B1 in immunoassay-based methods显示文摘Farzamfar B Bayanoihagh S Mahboudi F 2007Iranian Journal of Pharmaceutical Research2007,6,3:1
10Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients显示文摘AIM: To characterize the clinical, serologic and virologic features of hepatitis B virus (HBV) infection in Iranian patients with different stages of liver disease. METHODS: Sixty two patients comprising of 12 inactive carriers, 30 chronic hepatitis patients, 13 patients with liver cirrhosis and 7 patients with hepatocellular carcinoma (HCC) were enrolled in the study. The HBV S, C and basal core promoter (BCP) regions were amplified and sequenced, and the clinical, serologic, phylogenetic and virologic characteristics were investigated. RESULTS: The study group consisted of 16 HBeAg- positive and 46 HBeAg-negative patients. Anti-HBe- positive patients were older and had higher levels of ALT, ASL and bilirubin compared to HBeAg-positivepatients. Phylogenetic analysis revealed that all patients were infected with genotype D (mostly ayw2). The G1896A precore (PC) mutant was detected in 58.1% patients. HBeAg-negative patients showed a higher rate of PC mutant compared to HBeAg-positive patients (χ2 = 9.682, P = 0.003). The majority of patients with HCC were HBeAg-negative and were infected with PC mutant variants. There was no significant difference in the occurrence of BCP mutation between the two groups, while the rate of BCP plus PC mutants was higher in HBeAg-negative patients (χ2 = 4.308, P = 0.04). In the HBV S region, the genetic variability was low, and the marked substitution was P120T/S, with a rate of 9.7% (n = 6). CONCLUSION: In conclusion, HBV/D is the predominant genotype in Iran, and the nucleotide variability in the BCP and PC regions may play a role in HBV disease outcome in HBeAg-negative patients.Golnaz Bahramali Majid Sadeghizadeh Samad Amini-Bavil-Olyaee Seyed-Moayed Alavian Abbas Behzad-Behbahani Ahmad Adeli Mohammad-Reza Aghasadeghi Safieh Amini Fereidoun Mahboudi 2008World Journal of Gastroenterology2008,14,35:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费